Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA

www.emdgroup.com/en

Latest From Merck KGaA

Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Asia Pacific Commercial

Finance Watch: Landos Raises $60m Series B Round Ahead Of Phase II Data In 2020

If Landos goes public late next year, its financing strategy will align with venture capital and IPO trends observed in a new Jefferies report. Also, D&D Pharmatech raises $137.1m in VC cash, Sonnet secures up to $100m and the CF Foundation commits up to $15m to Arcturus.

Financing Business Strategies

GSK's New US Pharmaceuticals President Martinez-Davis Brings Oncology Experience

US Pharmaceuticals President Jack Bailey will step down, to be succeeded by Maya Martinez-Davis, currently at Merck KGAA.

Leadership Launches

Merck KGaA Moves MS Hopeful Evobrutinib To Phase III, Plans Pipeline Update

Merck KGaA said its second-quarter performance was boosted by its Life Science lab unit and milestone payments from drug development partners and promised analysts a pipeline update next month.

Commercial Companies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register